Alpha-Mannosidosis – Pipeline Review, H2 2011

Alpha-Mannosidosis – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Alpha-Mannosidosis - Pipeline Review, H2 2011', provides an overview of the Alpha-Mannosidosis therapeutic pipeline. This report provides information on the therapeutic development for Alpha-Mannosidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha-Mannosidosis. 'Alpha-Mannosidosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Alpha-Mannosidosis.
• A review of the Alpha-Mannosidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Alpha-Mannosidosis pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Alpha-Mannosidosis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Alpha-Mannosidosis pipeline depth and focus of Alpha-Mannosidosis therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Alpha-Mannosidosis Overview
Therapeutics Development
An Overview of Pipeline Products for Alpha-Mannosidosis
Alpha-Mannosidosis Therapeutics under Development by Companies
Alpha-Mannosidosis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Alpha-Mannosidosis Therapeutics – Products under Development by Companies
Alpha-Mannosidosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Alpha-Mannosidosis Therapeutics Development
Zymenex A/S
Alpha-Mannosidosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Lamazym - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Campath-1H + Cyclophosphamide + Busulfan + Allogeneic Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Busulfan + Cyclophosphamide + Antithymocyte Globulin + Hematopoietic Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Campath + Busulfan + Cyclophosphamide + Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Alpha-Mannosidosis Therapeutics – Drug Profile Updates
Alpha-Mannosidosis – Product Development Milestones
Featured News & Press Releases
Jan 25, 2011: Zymenex Completes Phase I Trials For Lamazym In Alpha-Mannosidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Alpha-Mannosidosis, H2 2011
Products under Development for Alpha-Mannosidosis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Zymenex A/S, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Alpha-Mannosidosis Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Alpha-Mannosidosis, H2 2011
Products under Development for Alpha-Mannosidosis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mid Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top